Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Calcified Tissue International
Published in: Calcified Tissue International 6/2003

01-12-2003

Estrogen Potentiates the Combined Effects of Transforming Growth Factor-β and Tumor Necrosis Factor-α on Adult Human Osteoblast-like Cell Prostaglandin E2 Biosynthesis

Authors: F. J. Secreto, A. Grover, M. Pacurari, M. B. Rice, M. Kantorow, A. P. Bidwai, J. D. Blaha, P. E. Keeting

Published in: Calcified Tissue International | Issue 6/2003

Login to get access

Abstract

Reports that estrogen treatment modulates arachidonic acid metabolism by bone and bone cells are found in the literature. However, conflicting indications of the relationship that exists between estrogen and arachidonic acid metabolism emerge from the analysis of those reports. The present studies were undertaken to determine if estrogen effected the production of prostaglandins (PG) in human osteoblast-like (hOB) cell cultures derived from adults, under basal or cytokine-stimulated conditions. A 48-hour estrogen pretreatment did not modify hOB cell PG biosynthesis on a qualitative basis, and PGE2 formation predominated under all tested conditions. Estrogen pretreatment did lead to increased PGE2 production in specimens stimulated conjointly with transforming growth factor-β1 and tumor necrosis factor-α (p < 0.001). No changes in PGE2 production were observed in estrogen pretreated specimens stimulated singly with either tested cytokine, nor in samples in which either TGFβ or TNF was replaced by interleukin-1β. Anti-estrogen (ICI 164,384) inclusion prevented the estrogen-dependent increase in PGE2 production in the TGFβ plus TNF-stimulated samples. These results suggest that an estrogen effect on bone cell prostaglandin biosynthesis may be most evident and significant under conditions in which the cells are exposed to multiple osteotropic cytokines, a condition that applies during the bone remodeling process.
Literature
1.
2.
Manolagas SC, Kousteni S, Jilka RL (2002) “Sex steroids and bone.” Recent Prog Horm Res 57:385–409CrossRefPubMed
3.
Spelsberg TC, Subramaniam M, Riggs BL, Khosla S (1999) “The actions and interactions of sex steroids and growth factors/cytokines on the skeleton.” Molec Endocrinol 13:819–828CrossRef
4.
Manolagos SC (2000) “Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis.” Endocr Rev 21:115–137
5.
Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF (1996) “Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β.” Nat Med 2:1132–1136CrossRefPubMed
6.
Gohel A, McCarthy M-B, Gronowicz G (1999) “Estrogen prevents glucocorticoid-induced apoptosis in osteoblasts in vivo and in vitro.” Endocrinology 140:5339–5347PubMed
7.
Pivirotto LA, Cissel DS, Keeting PE (1995) “Sex hormones mediate interleukin-1β production by human osteoblastic HOBIT cells.” Mol Cell Endocrinol 111:67–74CrossRefPubMed
8.
Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, Boyce B, Broxmeyer H, Manolagos SC (1992) “Increased osteoclast development after estrogen loss: mediation by interleukin-6.” Science 257:88–91CrossRefPubMed
9.
Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL (1999) “Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells.” Endocrinology 140:4367–4370PubMed
10.
Oursler MJ, Cortese C, Keeting PE, Anderson M, Bonde S, Riggs BL, Spelsberg TC (1991) “Modulation of transforming growth factor beta production in normal human osteoblast-like cells by 17[β]-estradiol and parathyroid hormone.” Endocrinology 129:3313–3320CrossRefPubMed
11.
Oursler MJ (1998) “Estrogen regulation of gene expression in osteoblasts and osteoclasts.” Clin Rev Eukaryot Gene Expr 8:125–140CrossRef
12.
Xu JQ, Cissel DS, Varghese S, Whipkey DL, Blaha JD, Graeber GM, Keeting PE (1997) “Cytokine regulation of adult human osteoblast-like cell prostaglandin biosynthesis.” J Cell Biochem 64:618–631CrossRefPubMed
13.
Robey PG, Young MF, Flanders KC, Roche NS, Kondaiah P, Reddi AH, Termine JD, Sporn MB, Roberts AB (1987) “Osteoblasts synthesize and respond to TGFβ in vitro. J Cell Biol 105:457–463CrossRefPubMed
14.
Gowen M, Chapman K, Littlewood A, Hughes D, Evans D, Russell RGG (1990) “Production of tumor necrosis factor by human osteoblasts is modulated by other cytokines, but not by osteotropic hormones.” Endocrinology 126:1250–1255CrossRefPubMed
15.
Keeting PE, Rifas L, Harris SA, Colvard DS, Spelsberg TC, Peck WA, Riggs BL (1991) “Evidence for interleukin-1β production by cultured normal human osteoblast-like cells.” J Bone Miner Res 6:827–833CrossRefPubMed
16.
Dodds RA, Merry K, Littlewood A, Gowen M (1994) “Expression of mRNA for IL1 beta, IL6 and TGFbeta 1 in developing human bone and cartilage.” Histochem Cytochem 42:733–744CrossRef
17.
Kawaguchi H, Pilbeam CC, Harrison JR, Raisz LG (1995) “The role of prostaglandins in the regulation of bone metabolism.” Clin Orthop Rel Res 313:36–46
18.
19.
Cissel DS, Murty M, Whipkey DL, Blaha JD, Graeber GM, Keeting PE (1996) “Estrogen pretreatment increases arachidonic acid release by bradykinin-stimulated normal human osteoblast-like cells.” J Cell Biochem 60:260–270CrossRefPubMed
20.
Borke JL, Eriksen EF, Minami J, Keeting P, Mann KG, Penniston JT, Riggs BL, Kumar R (1988) “Epitopes of the human erythrocyte Ca2+-Mg2+ ATPase pump in human osteoblast-like cell plasma membranes.” J Clin Endocrinol Metab 67:1299–1304CrossRefPubMed
21.
Marie PJ (1994) “Human osteoblast-like cells: a potential tool to assess the etiology of pathologic bone formation.” J Bone Miner Res 9:1847–1850CrossRefPubMed
22.
23.
Cissel DS, Birkle DL, Whipkey DL, Blaha JD, Graeber GM, Keeting PE (1995) “1,25-Dihydroxyvitamin D3 or dexamethasone modulate arachidonic acid uptake and distribution into glycerophospholipids by normal adult human osteoblast-like cells.” J Cell Biochem 57:599–609CrossRefPubMed
24.
Clark JD, Lin L, Kriz RW, Ramesha CS, Sultzman LA, Lin AY, Milona N, Knopf JL (1991) “A novel arachidonic acid-selective cytosolic phospholipase A2 contains a Ca2+ -dependent translocation domain with homology to PKC and GAP.” Cell 65:1043–1051CrossRefPubMed
25.
Keeting PE, Li CH, Murty M, Xu J, Cissel DS, Whipkey DL, Graeber GM, Blaha JD (1998) “Arachidonic acid metabolism by adult human osteoblast-like cells exhibits sexually dimorphic characteristics.” J Cell Biochem 71:74–81CrossRefPubMed
26.
Feyen JHM, Raisz LG (1987) “Prostaglandin production from sham-operated and ovariectomized rats: effects of 17β-estradiol in vivo.” Endocrinology 121:819–821CrossRefPubMed
27.
Pilbeam CC, Klein-Nulend J, Raisz LG (1989) “Inhibition by 17β-estradiol of PTH-stimulated resorption and prostaglandin production in cultured neonatal mouse calvariae.” Biochem Biophys Res Commun 163:1319–1324CrossRefPubMed
28.
Lane N, Coble T, Kimmel DB (1990) “Effects of naproxen on cancellous bone in ovariectomized rats.” J Bone Miner Res 5:1029–1035CrossRefPubMed
29.
Raisz LG (1995) “Physiologic and pathologic roles of prostaglandins and other eicosanoids in bone metabolism.” J Nutr 125:2024S–2027SPubMed
30.
Jee WSS, Ueno K, Deng YP, Woodbury DM (1985) “The effects of prostaglandin E2 in growing rats: increased metaphyseal hard tissue and cortico-endosteal bone formation.” Calcif Tissue Int 37:148–157CrossRefPubMed
31.
Jee WSS, Mori S, Li XJ, Chan S (1990) “Prostaglandin E2 enhances cortical bone mass and activates intracortical bone remodeling in intact and ovariectomized female rats.” Bone 11:253–266CrossRefPubMed
32.
Kimmel DB, Slovik DM, Lane NE (1994) “Current and investigational approaches for reversing established osteoporosis.” Rheum Dis Clin North America 20:735–758
33.
Mori S, Jee WSS, Li XJ (1992) “Production of new trabecular bone in osteopenic ovariectomized rats by prostaglandin E2.” Calcif Tissue Int 50:80–87CrossRefPubMed
34.
Welch RD, Johnston CE, Waldron MJ, Poteet B (1993) “Intraosseous infusion of PGE2 in the caprine tibia.” J Orthop Res 11:110–121CrossRefPubMed
35.
Sibonga JD, Bell NH, Turner RT (1998) “Evidence that ibuprofen antagonizes selective actions of estrogen and tamoxifen on rat bone.” J Bone Miner Res 13:863–870CrossRefPubMed
36.
Samuels A, Perry MJ, Tobias JH (1999) “High-dose estrogen-induced osteogenesis in the mouse is partially suppressed by indomethacin.” Bone 25:675–680CrossRefPubMed
37.
Kopp E, Ghosh S (1994) “Inhibition of NKκB by sodium salicylate and aspirin.” Science 265:956–959CrossRefPubMed
38.
Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA (1997) “Peroxisome proliferator-activated receptors are activated by indomethacin and other non-steroidal antiinflammatory drugs.” J Biol Chem 272:3406–3410CrossRefPubMed
39.
Paik JH, Ju JH, Lee JY, Boudreau MD, Hwang DH (2000) “Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase.” J Biol Chem 275:28173–28179PubMed
40.
Raisz LG (1999) “Physiology and pathophysiology of bone remodeling.” Clin Chem 45:1353–1358PubMed
41.
Smith WL, DeWitt DL (1996) “Prostaglandin endoperoxide H synthases-1 and -2.” Adv Immunol 62:167–215CrossRefPubMed
42.
Murakami M, Kambe T, Shimbara S, Kudo I (1999) “Functional coupling between various phospholipase A2’s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways.” J Biol Chem 274:3103–3115CrossRefPubMed
43.
Fujishima H, Sanchez Mejia RO, Bingham CO III, Lam BK, Sapirstein A, Bonventre JV, Austen KF, Arm JP (1999) “Cytosolic phospholipase A2 is essential for both the immediate and the delayed phases of eicosanoid generation in mouse bone-derived mast cells.” Proc Natl Acad Sci 96:4803–4807CrossRefPubMedPubMedCentral
44.
Breton M, Colyard O (1991) “Protein kinase C promotes arachidonate mobilization through enhancement of Co-A-independent transacylase activity in platelets.” Biochem J 280:93–98CrossRefPubMedPubMedCentral
45.
O’Doherty PJA (1978) “1,25-Dihydroxyvitamin D3 increases the activity of the intestinal phosphatidylcholine deacylation-reacylation cycle.” Lipids 14:75–77CrossRef
46.
Keeting PE, Li CH, Whipkey DL, Thweatt R, Xu JQ, Murty M, Blaha JD, Graeber GM (1998) 1,25-Dihydroxyvitamin D3 pretreatment limits prostaglandin biosynthesis by cytokine-stimulated adult human osteoblast-like cells. J Cell Biochem 68:237–246CrossRefPubMed
47.
Jun SS, Chen Z, Pace MC, Shaul PW (1998) “Estrogen upregulates cyclooxygenase-1 gene expression in ovine fetal pulmonary artery endothelium.” J Clin Invest 102:176–183CrossRefPubMedPubMedCentral
48.
Sato T, Michizu H, Hashizume K, Ito A (2001) “Hormonal regulation of PGE2 and COX-2 production in rabbit uterine cervical fibroblasts.” J Appl Physiol 90:1227–1231CrossRefPubMed
49.
Akarasereenont P, Techatraisak K, Thaworn A, Chotewuttakorn S (2000) “The induction of cyclooxygenase-2 by 17β-estradiol in endothelial cells is mediated through protein kinase C.” Inflamm Res 49:460–465CrossRefPubMed
50.
Turner RT, Evans GL, Wakley GK (1993) “Mechanism of action of estrogen on cancellous bone balance in tibiae of ovariectomized growing rats: inhibition of indices of formation and resorption.” J Bone Miner Res 8:359–365CrossRefPubMed
51.
Turner RT, Riggs BL, Spelsberg TC (1994) “Skeletal effects of estrogen.” Endocr Rev 15:275–300PubMed
52.
Lindsay R (1987) “The menopause: sex steroids and osteoporosis.” Clin Obstet Gynecol 30:847–858CrossRefPubMed
53.
Keeting PE, Scott RE, Colvard DS, Han IK, Spelsberg TC, Riggs BL (1991) “Lack of a direct effect of estrogen on proliferation and differentiation of normal human osteoblast-like cells.” J Bone Miner Res 6:827–833CrossRefPubMed
54.
Robinson JA, Harris SA, Riggs BL, Spelsberg TC (1997) “Estrogen regulation of human osteoblastic cell proliferation and differentiation.” Endocrinology 138:2919–2927PubMed
55.
Oursler MJ, Cortese C, Keeting PE, Anderson M, Bonde S, Riggs BL, Spelsberg TC (1991) “Modulation of TGFβ production in normal human osteoblast-like cells by 17β-estradiol and parathyroid hormone.” Endocrinology 129:3313–3320CrossRefPubMed
56.
Girasole G, Jilka RL, Passeri G, Bowell S, Boder G, Williams DS, Manolagas SC (1992) “17β-Estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens.” J Clin Invest 89:883–891CrossRefPubMedPubMedCentral
57.
Kassem M, Harris SA, Spelsberg TC, Riggs BL (1996) “Estrogen inhibits interleukin-6 production and gene expression in a human osteoblastic cell line with high levels of estrogen receptors.” J Bone Miner Res 11:193–199CrossRefPubMed
Metadata
Title
Estrogen Potentiates the Combined Effects of Transforming Growth Factor-β and Tumor Necrosis Factor-α on Adult Human Osteoblast-like Cell Prostaglandin E2 Biosynthesis
Authors
F. J. Secreto
A. Grover
M. Pacurari
M. B. Rice
M. Kantorow
A. P. Bidwai
J. D. Blaha
P. E. Keeting
Publication date
01-12-2003
Publisher
Springer New York
Published in
Calcified Tissue International / Issue 6/2003
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-002-0023-z

Other articles of this Issue 6/2003

Calcified Tissue International 6/2003 Go to the issue

OriginalPaper

Three-dimensional distribution of bone density in the proximal humerus

Laboratory Investigations

In-Situ Visualization and Quantification of Mineralization of Cultured Osteogenetic Cells

Announcements

Announcements

Clinical Investigations

Role of Vitamin D and Parathyroid Hormone in the Regulation of Bone Turnover and Bone Mass in Men: The MINOS Study

Laboratory Investigations

A Rapid Multiparameter Approach to Study Factors that Regulate Osteoclastogenesis: Demonstration of the Combinatorial Dominant Effects of TNF-α and TGF-ß in RANKL-Mediated Osteoclastogenesis

Index

Author Index
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits